271 related articles for article (PubMed ID: 33653401)
1. Effects of glucocorticoid pulse therapy on thyroid function and thyroid antibodies in children with graves' disease.
Hu Y; Man Y; Sun X; Xue Y
Ital J Pediatr; 2021 Mar; 47(1):46. PubMed ID: 33653401
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves' disease: a cross-sectional study.
Katahira M; Tsunekawa T; Mizoguchi A; Yamaguchi M; Tsuru K; Takashima H; Terada R
Hormones (Athens); 2023 Jun; 22(2):253-261. PubMed ID: 36811756
[TBL] [Abstract][Full Text] [Related]
3. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease.
Xu B; Wu D; Ying H; Zhang Y
Turk J Med Sci; 2019 Jun; 49(3):715-722. PubMed ID: 31023005
[TBL] [Abstract][Full Text] [Related]
4. Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease.
Kubota S; Ohye H; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Kuma K; Miyauchi A
Endocr J; 2005 Dec; 52(6):735-41. PubMed ID: 16410666
[TBL] [Abstract][Full Text] [Related]
5. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
Choi YM; Kwak MK; Hong SM; Hong EG
Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
[TBL] [Abstract][Full Text] [Related]
6. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
7. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K
Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311
[TBL] [Abstract][Full Text] [Related]
8. [Thyroid hormone changes in women with pre-eclampsia and its relationship with the presence of pre-eclampsia].
Zhou J; Du J; Ma B; Liu X; Qiu H; Li J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 2014 Feb; 49(2):109-13. PubMed ID: 24739642
[TBL] [Abstract][Full Text] [Related]
9. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
10. Correlation between serum beta-human chorionic gonadotropin levels and thyroid metabolic function in pregnant women with hyperemesis gravidarum.
Zheng H; Wang Q; Chen F
Chin J Physiol; 2023; 66(5):359-364. PubMed ID: 37929347
[TBL] [Abstract][Full Text] [Related]
11. Serum thyroglobulin is associated with orbitopathy in Graves' disease.
Khamisi S; Lundqvist M; Emadi P; Almby K; Ljunggren Ö; Karlsson FA
J Endocrinol Invest; 2021 Sep; 44(9):1905-1911. PubMed ID: 33515213
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
13. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
14. Thyroid-stimulating antibody in a patient with euthyroid Graves' disease.
Kubo T; Toki J; Kado Y; Kurihara M; Moriwake T; Kanzaki S; Seino Y
Endocr J; 2000 Apr; 47(2):197-201. PubMed ID: 10943745
[TBL] [Abstract][Full Text] [Related]
15. Low Vitamin D Status is Associated with Increased Thyrotropin-Receptor Antibody Titer in Graves Disease.
Zhang H; Liang L; Xie Z
Endocr Pract; 2015 Mar; 21(3):258-63. PubMed ID: 25370319
[TBL] [Abstract][Full Text] [Related]
16. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
[TBL] [Abstract][Full Text] [Related]
17. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of bone turnover markers and thyroid indicators for bone metabolism in GD patients after treatment.
Su M; Chai J; Zheng W; Jia Q; Tan J; He Y; Zhang R; Men J; Liu W; Shi T; Ren J; Dong L; Liu L; Meng Z
Front Endocrinol (Lausanne); 2024; 15():1301213. PubMed ID: 38742199
[TBL] [Abstract][Full Text] [Related]
19. Chronic recurrent stress due to panic disorder does not precipitate Graves' disease.
Chiovato L; Marinò M; Perugi G; Fiore E; Montanelli L; Lapi P; Cavaliere R; Ciampi M; Patronelli A; Placidi G; Placidi GF; Cassano GB; Pinchera A
J Endocrinol Invest; 1998 Dec; 21(11):758-64. PubMed ID: 9972676
[TBL] [Abstract][Full Text] [Related]
20. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
Siderova M; Hristozov K; Tsukeva A
Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
